Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

Xingmei Duan,1,2,* Minjie Mu,3,* Junfeng Yan,1 Lan Bai,1 Lei Zhong,1 Yuxuan Zhu,1 Haixia Pan,1 Mei Zhang,3 Jianyou Shi1,3 1Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People`s Hospital, Chengdu, 2State Key Laboratory of Biotherapy and Can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Duan X, Mu M, Yan J, Bai L, Zhong L, Zhu Y, Pan H, Zhang M, Shi J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	RNA interference Aurora-A kinase inhibitor liposome co-delivery melanoma apoptosis. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/1dc923d6e765497b874a3252b5f1e751
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1dc923d6e765497b874a3252b5f1e751
record_format	dspace
spelling	oai:doaj.org-article:1dc923d6e765497b874a3252b5f1e7512021-12-02T02:49:10ZCo-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy1178-2013https://doaj.org/article/1dc923d6e765497b874a3252b5f1e7512018-03-01T00:00:00Zhttps://www.dovepress.com/co-delivery-of-aurora-a-inhibitor-xy-4-and-bcl-xl-sirna-enhances-antit-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xingmei Duan,1,2,* Minjie Mu,3,* Junfeng Yan,1 Lan Bai,1 Lei Zhong,1 Yuxuan Zhu,1 Haixia Pan,1 Mei Zhang,3 Jianyou Shi1,3 1Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People`s Hospital, Chengdu, 2State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 3Key Laboratory Standardization of Chinese Herbal Medicines of Ministry of Education, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Medicine (TCM), Chengdu, People’s Republic of China *These authors contributed equally to this work Background: The newly synthesized Aurora-A kinase inhibitor XY-4 is a potential anti-cancer agent, but its hydrophobicity and limited efficiency restrict further application. Nanotechnology based combined therapy provides an optimized strategy for solving these issues.Methods: In this study, the newly synthesized Aurora-A kinase inhibitor XY-4 and Bcl-xl targeted siRNA were co-delivered by cationic liposomes, creating an injectable co-delivery formulation. The anti-cancer ability and mechanisms of XY-4/Bcl-xl siRNA co-loaded cationic liposomes were studied both in vitro and in vivo.Results: The prepared liposomes had a mean particle size of 91.3±4.5 nm with a zeta potential of 38.5±0.5 mV and were monodispersed (Polydispersity index =0.183) in water solution, with high drug loading capacity and stability. Intriguingly, the positive charges of co-delivery liposomes not only facilitated gene delivery, but also obviously enhanced drug uptake. The XY-4/Bcl-xl siRNA co-loaded cationic liposomes demonstrated enhanced anti-cancer effects on B16 melanoma cells in vitro by activation mitochondrial apoptosis pathway. Moreover, intratumoral injection of this co-delivery formulation efficiently inhibited the growth of a B16 melanoma xenograft model in vivo.Conclusion: By co-delivering Aurora-A kinase inhibitor XY-4 and Bcl-xl targeting siRNA in a nanoformulation, our study supplied a potential combination strategy for melanoma therapy. Keywords: RNA interference, Aurora-A kinase inhibitor, liposome, co-delivery, melanoma, apoptosisDuan XMu MYan JBai LZhong LZhu YPan HZhang MShi JDove Medical PressarticleRNA interferenceAurora-A kinase inhibitorliposomeco-deliverymelanomaapoptosis.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 1443-1456 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	RNA interference Aurora-A kinase inhibitor liposome co-delivery melanoma apoptosis. Medicine (General) R5-920
spellingShingle	RNA interference Aurora-A kinase inhibitor liposome co-delivery melanoma apoptosis. Medicine (General) R5-920 Duan X Mu M Yan J Bai L Zhong L Zhu Y Pan H Zhang M Shi J Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
description	Xingmei Duan,1,2,* Minjie Mu,3,* Junfeng Yan,1 Lan Bai,1 Lei Zhong,1 Yuxuan Zhu,1 Haixia Pan,1 Mei Zhang,3 Jianyou Shi1,3 1Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People`s Hospital, Chengdu, 2State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 3Key Laboratory Standardization of Chinese Herbal Medicines of Ministry of Education, State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Medicine (TCM), Chengdu, People’s Republic of China *These authors contributed equally to this work Background: The newly synthesized Aurora-A kinase inhibitor XY-4 is a potential anti-cancer agent, but its hydrophobicity and limited efficiency restrict further application. Nanotechnology based combined therapy provides an optimized strategy for solving these issues.Methods: In this study, the newly synthesized Aurora-A kinase inhibitor XY-4 and Bcl-xl targeted siRNA were co-delivered by cationic liposomes, creating an injectable co-delivery formulation. The anti-cancer ability and mechanisms of XY-4/Bcl-xl siRNA co-loaded cationic liposomes were studied both in vitro and in vivo.Results: The prepared liposomes had a mean particle size of 91.3±4.5 nm with a zeta potential of 38.5±0.5 mV and were monodispersed (Polydispersity index =0.183) in water solution, with high drug loading capacity and stability. Intriguingly, the positive charges of co-delivery liposomes not only facilitated gene delivery, but also obviously enhanced drug uptake. The XY-4/Bcl-xl siRNA co-loaded cationic liposomes demonstrated enhanced anti-cancer effects on B16 melanoma cells in vitro by activation mitochondrial apoptosis pathway. Moreover, intratumoral injection of this co-delivery formulation efficiently inhibited the growth of a B16 melanoma xenograft model in vivo.Conclusion: By co-delivering Aurora-A kinase inhibitor XY-4 and Bcl-xl targeting siRNA in a nanoformulation, our study supplied a potential combination strategy for melanoma therapy. Keywords: RNA interference, Aurora-A kinase inhibitor, liposome, co-delivery, melanoma, apoptosis
format	article
author	Duan X Mu M Yan J Bai L Zhong L Zhu Y Pan H Zhang M Shi J
author_facet	Duan X Mu M Yan J Bai L Zhong L Zhu Y Pan H Zhang M Shi J
author_sort	Duan X
title	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
title_short	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
title_full	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
title_fullStr	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
title_full_unstemmed	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy
title_sort	co-delivery of aurora-a inhibitor xy-4 and bcl-xl sirna enhances antitumor efficacy for melanoma therapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/1dc923d6e765497b874a3252b5f1e751
work_keys_str_mv	AT duanx codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT mum codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT yanj codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT bail codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT zhongl codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT zhuy codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT panh codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT zhangm codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy AT shij codeliveryofauroraainhibitorxy4andbclxlsirnaenhancesantitumorefficacyformelanomatherapy
_version_	1718402088850948096

Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

Ejemplares similares